Lilly Teams Up With Synthes To Develop and Commercialize Bone Healing Therapies
This article was originally published in The Pink Sheet Daily
Drug-device company development collaborations are common, but the range, commercial nature and expected duration of the Synthes/Lilly deal is unusual.
You may also be interested in...
Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.
Johnson & Johnson will control a majority of the orthopedic trauma device market and double its stake in the spinal device field by acquiring Synthes for $21.3 billion under a definitive agreement announced April 27.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?